CJC-1295 + Ipamorelin Dosing Math, Step by Step

CJC-1295 and Ipamorelin are the most common peptide pairing people ask about, and the dosing question is confusing because you’re dealing with a blend: one vial, one powder, two peptides. You can’t look up “the CJC-1295 dose” and “the ipamorelin dose” and treat them separately, because a single draw pulls both at once. This guide works the CJC-1295 ipamorelin dosage math from vial to syringe, step by step, using the peptide blend calculator logic so you can see exactly what one draw delivers.

Before the arithmetic, one honest framing note. The mechanism story behind this pair (a GHRH analog plus a selective GH secretagogue) is covered in how the CJC-1295 and Ipamorelin combo is supposed to work. The dosing math below is deterministic and reliable. The dosing numbers people quote are not: they come from clinics and forums, not controlled trials. Keep those two things separate as you read.

Why the two peptides are dosed as one unit

CJC-1295 is a growth-hormone-releasing-hormone (GHRH) analog; Ipamorelin is a growth-hormone-releasing peptide (GHRP) that, in the original characterization by Raun and colleagues, released GH without meaningfully raising ACTH or cortisol, the trait that earned it the label “first selective growth hormone secretagogue.” The pairing rationale is that they hit two different receptors, so a combined pulse is larger than either alone.

For dosing, though, the mechanism is beside the point. What matters is that they arrive pre-blended in one vial. When you reconstitute with a single volume of bacteriostatic water, both dissolve into one homogeneous solution. Every draw is a slice of the whole mixture, in whatever ratio the powder was blended. You dose the blend; you cannot dial one up without the other. That principle is the foundation of all blend dosing. See how to dose a peptide blend for the general case.

A note on the CJC-1295 variant

Two versions get sold under “CJC-1295”:

• CJC-1295 with DAC. A Drug Affinity Complex binds it to serum albumin, giving a long half-life. In the Teichman 2006 human study, a single subcutaneous dose produced an estimated half-life of 5.8–8.1 days and raised GH 2- to 10-fold for six days or more. This form is dosed roughly weekly.
• CJC-1295 without DAC (also called Modified GRF 1-29 / Mod GRF 1-29). No albumin binding, so it clears in minutes and is dosed more frequently, usually alongside each ipamorelin injection.

Most “CJC-1295 + Ipamorelin” blends use the no-DAC form, because both peptides are then short-acting and pulse together. The math below works identically either way (only the milligrams on the label feed the formula), but the variant changes how often the number is repeated per day. If the “with DAC vs no DAC” distinction is new, the combo overview linked above explains it.

The three-step math

Every blend dose is the same three steps, applied to each peptide.

Step 1: Concentration. Divide each peptide’s milligrams by the shared water volume:

Concentration = mg of that peptide ÷ mL of BAC water

Step 2: Convert your draw to volume. Insulin syringes read in “units,” not mL. On a standard U-100 syringe, 100 units = 1 mL, so:

1 unit = 0.01 mL

Step 3: Amount per draw. For each peptide:

Amount delivered = concentration × draw volume (mL)

Because the draw volume is shared, both peptides always come out in exactly the ratio of their milligrams.

Worked example: a 5 mg + 5 mg blend

Take a common vial: CJC-1295 (no DAC) 5 mg + Ipamorelin 5 mg, 10 mg of powder total. Reconstitute with 2 mL of bacteriostatic water.

Step 1, concentrations:

Peptide	In vial	÷ 2 mL	Concentration
CJC-1295	5 mg	÷ 2 mL	2.5 mg/mL = 2,500 mcg/mL
Ipamorelin	5 mg	÷ 2 mL	2.5 mg/mL = 2,500 mcg/mL

Step 2 & 3: say you want ~100 mcg of each. How many units is that? At 2,500 mcg/mL, 100 mcg is 100 ÷ 2,500 = 0.04 mL, and 0.04 mL ÷ 0.01 = 4 units.

Now confirm what a 4-unit (0.04 mL) draw delivers:

Peptide	Concentration	× 0.04 mL	Per draw
CJC-1295	2,500 mcg/mL	× 0.04	100 mcg
Ipamorelin	2,500 mcg/mL	× 0.04	100 mcg

So a 4-unit draw gives 100 mcg of each: a 1:1 ratio, matching the 5:5 mg you started with. Draw 8 units and you get 200 mcg of each; there is no draw that gives more CJC-1295 without proportionally more ipamorelin.

How many doses in the vial? At 4 units (0.04 mL) per dose from 2 mL total, that’s 2 ÷ 0.04 = 50 doses.

Worked example: an uneven blend

Blends aren’t always 1:1. Suppose the label reads CJC-1295 2 mg + Ipamorelin 5 mg, reconstituted with 2 mL:

Peptide	In vial	÷ 2 mL	Concentration
CJC-1295	2 mg	÷ 2 mL	1.0 mg/mL = 1,000 mcg/mL
Ipamorelin	5 mg	÷ 2 mL	2.5 mg/mL = 2,500 mcg/mL

A 4-unit (0.04 mL) draw now delivers:

Peptide	Concentration	× 0.04 mL	Per draw
CJC-1295	1,000 mcg/mL	× 0.04	40 mcg
Ipamorelin	2,500 mcg/mL	× 0.04	100 mcg

The ratio is fixed at 2:5. If you wanted 100 mcg of CJC-1295 here, you’d draw 10 units, but that would also drag ipamorelin to 250 mcg. The uneven ratio is baked in; the peptide blend calculator shows both numbers for any draw so you don’t have to eyeball it.

About those dose numbers

The “100 mcg of each, once or twice daily” figure is everywhere online, but it comes from clinic protocols and community practice, not controlled human trials. The strongest human data on this pair is thin. Teichman 2006 studied CJC-1295 with DAC alone (not the no-DAC form, not with ipamorelin), using weight-based doses of roughly 30–60 mcg/kg. Raun 1998 characterized ipamorelin’s selectivity in animals and cells. No controlled trial has tested the no-DAC-plus-ipamorelin combination that most blends contain. So use 100 mcg as an example input for the arithmetic, not as a validated dose.

Honest caveats

• Not approved for human use. CJC-1295 and ipamorelin are research chemicals; the combination has no controlled human safety data. Labeled milligram amounts are frequently unverified. If the label is wrong, every number above is wrong.
• The math is deterministic; the dose is not. Calculating what’s in a draw says nothing about whether taking it is safe or effective.
• Educational only. This is not medical advice. Consult a qualified clinician before considering anything in this space.

The takeaway

CJC-1295 + Ipamorelin is a blend, so the dosing math is blend math: concentration is each peptide’s mg over the shared water volume, 1 unit is 0.01 mL on a U-100 syringe, and a draw delivers concentration × volume for each peptide, always in the ratio the powder was blended. The arithmetic is trustworthy; the popular dose numbers are not, since no controlled trial has validated the combination. Run your actual label through the peptide blend calculator, and keep the evidence limits front of mind.

Sources

• Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805 — CJC-1295 (with DAC) half-life 5.8-8.1 days; GH raised 2- to 10-fold for 6+ days.
• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561 — ipamorelin releases GH without significantly raising ACTH or cortisol.
• U-100 insulin-syringe conversion (1 unit = 0.01 mL) and concentration/volume relationships are deterministic arithmetic.